SubHero Banner

Lonsurf® (trifluridine/tipiracil) – New indication

Februarys 25, 2019 - Taiho Oncology announced the FDA approval of Lonsurf (trifluridine/tipiracil), for the treatment of adult patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

Download PDF